Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Sifrol® Onset of Action and Impact on RLS: A 12-week Observational Study in Patients With Primary RLS

The objectives of this Post Marketing Surveillance (PMS) are:

• Evaluation of the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Syndrome Scale (IRLS) and Clinical Global Impression Improvement scale (CGI- I)
• Evaluation of the time to reaching maintenance dose of pramipexole
• Evaluation of work productivity impairment associated with RLS based on the Work Productivity and Activity Impairment Questionnaire (WPAI) questionnaire

Inclusion Criteria:

• Patients suffering from primary RLS who are eligible for Pramipexol (PPX) treatment could be included into the study
• Patients not pre-treated with any dopaminergic agent (de novo patients) or patients pre-treated with dopaminergic medication
• Male of female patients of any age

Exclusion Criteria:

• The treating physicians are asked to consider the regulations described in the Summary of Product Characteristics (SmPC) for the treatment with pramipexole